Impact of Ethnicity and Race in Cardiometabolic Health:
Implications for Risk Assessment and Management
12:00 - 1:00 PM |
Virtual PME Symposium (Non-CME) The Interconnected Cardio-Renal-Metabolic (CRM) Systems Eden Miller, DO; Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc and Lilly USA, LLC. |
1:00 - 1:15 PM |
Active Stretch Session with NASM-Certified Fitness Instructor Aria Aloi |
1:15 - 1:15 PM |
Opening Remarks |
1:15 - 1:35 PM |
The Role of Racial, Ethnic, and Social Factors in Cardiometabolic Health: An Overview |
1:35 - 1:55 PM |
Managing T2D in the Hispanic/Latino Population A. Enrique Caballero, MD |
1:55 - 2:15 PM |
A Polypill for Prevention of Cardiovascular Disease in Racial Minorities: Can We Bridge the Gap? Daniel Muñoz, MD, MPA |
2:15 - 2:45 PM |
Evolving Treatment Paradigms, New Therapies, New Guidelines, But at What Cost? |
2:45 - 3:15 PM |
Expert Panel Discussion and Audience Q & A Chair: Keith C. Ferdinand, MD |
3:15 - 3:45 PM |
Company Spotlight Break |
3:45 - 4:45 PM |
Primetime CME Symposium |
4:45 - 5:05 PM |
Do Diabetes Cardiovascular Outcomes Trials Have a Minority Problem? |
5:05 - 5:25 PM |
The Racial and Ethnic Differences in Cardiometabolic Risk Factors and What They Mean for Your Practice |
5:25 - 5:45 PM |
How Should You Counsel Patients Who Live in Food Deserts? |
5:45 - 6:15 PM |
Expert Panel Discussion and Audience Q & A Chair: Keith C. Ferdinand, MD |
6:15 - 6:30 PM |
Refresh and Recharge Break |
6:30 - 7:30 PM |
Virtual PME Symposium (Non-CME) An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C Eliot A. Brinton, MD, FAHA, FNLA, FACE Sponsored by Esperion Therapeutics. |
Session IV: Obesity & Lifestyle
8:15 AM |
Opening Remarks |
8:15 - 8:35 AM |
Physical Activity and Obesity Management |
8:35 - 9:05 AM |
Nutrition and Cardiometabolic Disorders Management |
9:05 - 9:45 AM |
NAFLD/NASH and the Continuum of Cardiometabolic Risk: Implications for Diagnosis & Management |
9:45 - 10:15 AM |
Company Spotlight Break |
10:15 - 10:35 AM |
What BMI Should Be Used for Metabolic Surgery? Supported by an educational grant from Medtronic. |
10:35 - 11:05 AM |
Behavioral Strategies in Obesity Management |
11:05 - 11:25 AM |
Obesity Paradox in Cardiovascular Disease - Is it Real? |
11:25 - 11:55 aM |
Expert Panel Discussion Chair: Robert H. Eckel, MD |
FDA Update and Keynote
7:00 - 8:00 AM |
Sunrise CME Symposium Chair: Marc P. Bonaca, MD Faculty: Deepak L. Bhatt, MD, MPH; Manesh R. Patel, MD Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. |
8:00 - 8:15 AM |
Refresh and Recharge Break |
8:15 - 9:45 AM |
Opening Remarks & FDA Update and Late Breaking Trials Chair: Christie M. Ballantyne, MD |
9:45 - 10:15 AM |
Keynote |
10:15 - 10:45 AM |
Company Spotlight Break |
10:45 - 11:45 AM |
Primetime CME Symposium Chair: Matthew R. Weir, MD |
SESSION I: Hypertension/Heart Failure/Kidney
11:45 - 11:50 AM |
Opening Remarks |
11:50 AM - 12:10 PM |
Understanding How to Interpret Signals from the Kidney When BP is Rapidly Controlled |
12:10 - 12:25 PM |
Refresh and Recharge Break |
12:25 - 1:25 PM |
Virtual PME Symposium (Non-CME) Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and the Importance of Reducing the Burden of Elevated LDL-C Levels Yehuda Handelsman, MD Sponsored by Novartis |
1:25 - 1:40 PM |
Active Stretch Session with NASM-Certified Fitness Instructor Aria Aloi |
1:40 - 2:00 PM |
Sleep and Blood Pressure Control: Implications for Hypertension |
2:00 - 2:20 PM |
From Bench to Bedside: Understanding Kidney Signals in the Setting of a Failing Heart John C. Burnett Jr., MD |
2:20 - 2:50 PM |
Company Spotlight Break |
2:50 - 3:50 PM |
Primetime CME Symposium Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches Chair: George L. Bakris, MD Faculty: Rajiv Agarwal, MD; Janet B. McGill, MD Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc. |
3:50 - 4:20 PM |
Transthyretin Cardiac Amyloidosis: An Underestimated Cause of HF |
4:20 - 5:05 PM |
Challenging Cardio-Renal Cases & Panel Discussion Chair: George L. Bakris, MD |
5:05 - 5:20 PM |
Refresh and Recharge Break |
5:20 - 6:20 PM |
Virtual PME Symposium (non-CME) VASCEPA® (icosapent ethyl): Elevating the Standard of Care Sponsored by Amarin Pharma, Inc. |
Session II: Dyslipidemia/Atherosclerosis/Thrombosis
8:15 AM |
Opening Remarks |
8:15 - 8:45 AM |
Beyond LDL: Targeting Inflammation to Reduce Cardiovascular Risk - Can Targeted Anti-Cytokine Therapy Prolong Life? |
8:45 - 9:45 AM |
Primetime CME Symposium |
9:45 - 10:15 AM |
Company Spotlight Break |
10:15 - 10:45 AM |
How Should High Lp(a) Levels Be Addressed? |
10:45 - 11:45 AM |
Challenging Lipid Management Cases & Panel Discussion Chair: Christie M. Ballantyne, MD |
11:45 AM - 12:00 PM |
Refresh and Recharge |
12:00 - 1:00 PM |
Virtual PME Symposium (non-CME) Close to the Heart: The Importance of Recognizing Cardiovascular Risk in Type 2 Diabetes John E. Anderson, MD Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. |
1:00 - 1:15 PM |
Active Stretch Session with NASM-Certified Fitness Instructor Aria Aloi |
Session III: Diabetes
1:15 - 1:20 PM |
Opening Remarks |
1:20 - 1:50 PM |
Insulin Resistance: A 2020 Update |
1:50 - 2:50 PM |
Primetime CME Symposium |
2:50 - 3:20 PM |
Emerging Targets in Diabetes Treatment: What Dual Agent Should Be Developed? |
3:20 - 3:50 PM |
Company Spotlight Break |
3:50 - 4:20 PM |
Expert Perspective: Disparities in Diabetes Guidelines |
4:20 - 5:20 PM |
Multi-disciplinary Cases in T2D and Expert Panel Discussion Chair: Anne L. Peters, MD |
5:20 - 5:25 PM |
Refresh and Recharge Break |
5:25 - 6:25 PM |
Primetime CME Symposium |